Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CR Gosun In-Licenses Antibiotic from Basilea in $153 Million Deal

publication date: Sep 28, 2017

China Resources Gosun Pharma in-licensed greater China rights to an antibiotic from Switzerland's Basilea Pharmaceutica in a deal worth up to $152 million. Zevtera^® (ceftobiprole) is effective against drug-resistant infections. CR Gosun will make an upfront payment of $3 million, and it will pay up to $149 million in regulatory and sales milestones. Zevtera is available in Europe and will soon start a US Phase III trial. More details....

Stock Symbol: (SIX: BSLN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.